Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sept. 23 Financial Quick Takes: Innate looks to add U.S. listing; plus Curamir's launch, Qihan Bio and Vedanta

Innate proposes U.S. listing
Innate Pharma S.A. (Euronext:IPH) filed to raise up to $100 million total across a NASDAQ listing and a European private placement. The antibody company markets CD22-targeted

Read the full 298 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE